Sigma Pharmaceuticals Delivers Solid Interim, Retail Strategy Gaining Traction; Raising Fair Value
Sigma reported better-than-expected underlying interim fiscal 2017 NPAT of AUD 31.7 million, up 14.5% on the prior corresponding period, on sales revenue of AUD 2.2 billion, up 28.1%. Excluding Hepatitis C, sales grew by 7.8% consisting of a 5% uplift derived from non-Pharmaceutical Benefit Scheme sales, or non-PBS sales, with the remaining 2.8% attributed to market share gains. Non-PBS sales represent mostly over the counter, or OTC, sales. This includes private and exclusive label products sup...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.